Cardiac and renal complications of carfilzomib in patients with multiple myeloma
Open Access
- 27 February 2017
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 1 (7) , 449-454
Abstract
Key Points: Carfilzomib is associated with reversible cardiotoxicity in 12% of consecutive myeloma patients. Transient renal toxicity is common, but carfilzomib may improve renal function in myeloma-related renal impairment.Keywords
This publication has 32 references indexed in Scilit:
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica, 2013
- Flow-Mediated Vasodilation in End-Stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2011
- Cardiotoxicity of the Anticancer Therapeutic Agent BortezomibThe American Journal of Pathology, 2010
- Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cellsBlood, 2009
- Intracellular Protein Aggregation Is a Proximal Trigger of Cardiomyocyte AutophagyCirculation, 2008
- Proteasome inhibitors: Poisons and remediesMedicinal Research Reviews, 2007
- Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the ProteasomeCancer Research, 2007
- Competing risk analysis using R: an easy guide for cliniciansBone Marrow Transplantation, 2007
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007
- Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cellsFree Radical Biology and Medicine, 2006